FAYUVI

This brand name is authorized in United States.

Active ingredients

The drug FAYUVI contains one active pharmaceutical ingredient (API):

1	Rebisufligene etisparvovec UNII V28L3Q0LVZ - REBISUFLIGENE ETISPARVOVEC
	Rebisufligene etisparvovec is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a functional copy of the human N-sulfoglucosamine sulfohydrolase (SGSH) gene to cells. Intravenous infusion of rebisufligene etisparvovec results in production of the lysosomal enzyme sulfamidase in target tissues with subsequent breakdown of heparan sulfate (HS) in lysosomes.
	Read more about Rebisufligene etisparvovec

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FAYUVI Suspension for infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AB29		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB29

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	69794-300, 69794-301, 69794-302, 69794-303, 69794-304, 69794-305, 69794-306, 69794-307, 69794-308, 69794-309, 69794-310, 69794-311, 69794-312, 69794-313, 69794-314, 69794-315, 69794-316, 69794-317, 69794-318, 69794-319, 69794-320, 69794-321, 69794-322, 69794-323, 69794-324, 69794-325, 69794-326, 69794-327, 69794-328, 69794-329, 69794-330, 69794-331